Merck 1Q: Januvia meets CVOT goals; Keytruda ready to go in NSCLC

Merck & Co saw worldwide sales fall by 8% in the first quarter of 2015 but major products met expectations – including diabetes therapy Januvia (sitagliptin), which received further positive news on 27 April when Merck reported the drug didn't increase the risk of heart problems in patients.

Full results of the cardiovascular outcomes (CVOT) trial for the di-peptidyl peptidase-IV (DPP-4) Januvia will be reported at the American...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Scholar Rock Shows Muscle-Building PoC In Obesity

18 Jun 2025

• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

11 Jun 2025

• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Metsera’s Amylin Analog Stars In Obesity Phase I

09 Jun 2025

• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.